Baseline characteristics for INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease
Arthur J Mayorga, Brady Burgess, Tuan Nguyen, Jingjing Gao, Giacomo Salvadore, Gary Romano · 2025
Read Baseline characteristics for INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease by Arthur J Mayorga, Brady Burgess, Tuan Nguyen, Jingjing Gao, Giacomo Salvadore, Gary Romano (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712814.txt.
Description
Six authors describe who joined a phase two trial of a new Alzheimer's antibody, in a 2025 paper. The drug, AL002, activates a receptor on the brain's immune cells and is the first of its kind tested for this disease. The trial, called INVOKE-2, randomly assigned patients to the drug or a dummy treatment across several dose arms. Treatment runs up to ninety-six weeks, plus a long extension.
381 people with early disease joined, with a median age of seventy-one. Two-thirds had mild memory impairment and one-third mild dementia, and all had amyloid confirmed before entry. About three in five carried one copy of a risk gene tied to brain scan side effects. Two-copy carriers were dropped early after scan changes appeared more often in that group. The authors say the group matches the intended early-stage population for testing the drug.
Catalog record
| CREATOR | Arthur J Mayorga, Brady Burgess, Tuan Nguyen, Jingjing Gao, Giacomo Salvadore, Gary Romano |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |